UPC Analytics
ENDE
Overview · Filed: Sep 2, 2024

UPC_CFI_503/2024

NOVEL ANTITUMORAL USE OF CABAZITAXEL

Parent infringement case:UPC_CFI_148/2024

RevocationCounter Claim for RevocationMunich LDCounter claim for revocationCase Closed
OverviewDecisionsDocumentsTimeline
Parties

Claimants

  • Zentiva, k.s.
  • Zentiva Pharma GmbH
  • Zentiva France

Respondents

Judges
  • Matthias Zigann
  • Alima Zana
  • Tobias Pichlmaier
Patents
  • EP2493466
CPC codes: A61K38/193, A61K31/573, A61P35/04, A61K31/164, A61K31/56, A61P43/00, A61P13/08, A61P15/00, A61K31/337, A61P35/00, A61K45/06, A61P25/16

Technology area: Pharmaceuticals · Small Molecule

Sector: Pharmaceutical & Medical

Outcome
—
Filed: Sep 2, 2024
First decided: Dec 12, 2025
Language: English
Open on UPC Registry